Cencora, Inc. (COR)
Automate Your Wheel Strategy on COR
With Tiblio's Option Bot, you can configure your own wheel strategy including COR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COR
- Rev/Share 1600.8183
- Book/Share 6.0878
- PB 55.1843
- Debt/Equity 7.7566
- CurrentRatio 0.8726
- ROIC 0.1023
- MktCap 55900491430.0
- FreeCF/Share 18.4486
- PFCF 15.6353
- PE 33.0078
- Debt/Assets 0.1103
- DivYield 0.0075
- ROE 2.4099
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | COR | Wells Fargo | Equal Weight | Overweight | -- | $337 | June 3, 2025 |
| Resumed | COR | Mizuho | -- | Outperform | -- | $280 | Dec. 4, 2024 |
| Downgrade | COR | BofA Securities | Buy | Neutral | $275 | $245 | Sept. 18, 2024 |
News
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Read More
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Read More
Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can distribute. Future share price targets point to significant potential upside over 3 years, justifying a buy despite the stock trading above average now.
Read More
Here's Why Cencora (COR) is a Strong Momentum Stock
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read More
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
Read More
Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Cencora, Inc. (NYSE:COR ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - President & Chief Executive Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Capital Lisa Gill - JPMorgan George Hill - Deutsche Bank Charles Rhyee - TD Cowen Eric Percher - Nephron Research Steven Valiquette - Mizuho Securities Allen Lutz - Bank of America Daniel Grosslight - Citi Kevin Caliendo - UBS Erin Wright …
Read More
Cencora (COR) Beats Q2 Earnings and Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) came out with quarterly earnings of $4.42 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.80 per share a year ago.
Read More
Cencora Reports Fiscal 2025 Second Quarter Results
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below.
Read More
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
Read More
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Read More
Cencora (COR) Earnings Expected to Grow: Should You Buy?
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Published: April 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Read More
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
Read More
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Negative
In the present market turbulence, investors may want to consider discounted stocks, such as FMS, PAHC and COR.
Read More
Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High
Published: April 04, 2025 by: Investors Business Daily
Sentiment: Positive
Cencora hit an all-time high on Friday. The post Sellers Rule The Roost Amid Tariff Wars, But This Stock Hits A High appeared first on Investor's Business Daily.
Read More
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
Read More
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Read More
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most.
Read More
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here is Why Growth Investors Should Buy Cencora (COR) Now
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Read More
Why Is Cencora (COR) Up 3.1% Since Last Earnings Report?
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Read More
Scoop Up These 3 GARP Stocks to Receive Handsome Returns
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, COR and AXP are some stocks that hold promise.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Cencora (COR)
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Cencora: Higher Potential Returns After Reduced Walgreens Stake
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ credit rating, and an active share repurchase program, enhancing shareholder returns. Strategic acquisitions like Retina Consultants of America position Cencora for long-term success, with management guiding for 10% annual EPS growth.
Read More
About Cencora, Inc. (COR)
- IPO Date 1995-04-04
- Website https://www.amerisourcebergen.com
- Industry Medical - Distribution
- CEO Dr. Robert P. Mauch Ph.D., PharmD
- Employees 42000